1253056-18-6

Basic information

• Product Name: Sitagliptin DeaMino IMpurity 1
• Synonyms: Sitagliptin DeaMino IMpurity 1;(2E)-1-[5,6-Dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-2-buten-1-one;(E)-1-(3-(trifluoroMethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)but-2-en-1-one;Sitagliptin iMpurity S;3-Desamino-2,3-dehydro Sitagliptin;Sitagliptin Impurity FP-D;Sitagliptin phenyl crotonyl analog
• CAS NO: 1253056-18-6
• Molecular Formula: C16H12F6N4O
• Molecular Weight: 390.2830992
• EINECS: 604-604-1
• Mol File: 1253056-18-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 517.5±60.0 °C(Predicted)
• Appearance: /
• Density: 1.52±0.1 g/cm3(Predicted)
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly), Methanol
• PKA: -0.06±0.20(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: Sitagliptin DeaMino IMpurity 1(CAS DataBase Reference)
• NIST Chemistry Reference: Sitagliptin DeaMino IMpurity 1(1253056-18-6)
• EPA Substance Registry System: Sitagliptin DeaMino IMpurity 1(1253056-18-6)

Safety Data

• Hazardous Substances Data: 1253056-18-6(Hazardous Substances Data)

Usage

Description

Sitagliptin DeaMino IMpurity 1, also known as 3-Desamino-2,3-dehydro Sitagliptin, is an impurity found in Sitagliptin (S491000), a trizolopyrazine dipeptidyl peptidase IV inhibitor. Sitagliptin has been approved for the therapy of type II diabetes and plays a crucial role in managing blood sugar levels in patients.

Uses

Used in Pharmaceutical Industry:
Sitagliptin DeaMino IMpurity 1 is used as an impurity in the production of Sitagliptin for the treatment of type II diabetes. The presence of this impurity is essential for the development and formulation of Sitagliptin, as it contributes to the overall effectiveness of the drug in managing blood sugar levels.
Sitagliptin DeaMino IMpurity 1 is used as a research compound for the study of its potential effects on the DPP-IV enzyme, which is involved in the regulation of blood glucose levels. Understanding the interactions and effects of this impurity can provide valuable insights into the development of more effective treatments for type II diabetes.
Additionally, Sitagliptin DeaMino IMpurity 1 can be used as a reference material for quality control and analytical testing in the pharmaceutical industry. This ensures the purity and efficacy of Sitagliptin, as well as the safety and reliability of the drug for patients.

Upstream product

• 1253056-01-7 (R/S)-3-hydroxy-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one 
• 764667-65-4 1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butane-1,3-dione 

Relevant articles and documents

EXPEDIENT SYNTHESIS OF SITAGLIPTIN

Novel intermediates are disclosed as intermediates for preparation of a Sitagliptin. A novel synthetic method to prepare Sitagliptin using the said intermediates is also disclosed.